Decentralised Clinical Trials: What Survived the Post-COVID Hype?

The pandemic promised a future where clinical trials could happen anywhere. Five years later, the reality is more complicated, and perhaps more promising.
When COVID-19 disrupted clinical research in 2020, the industry was forced to rethink how trials were conducted. Hospital visits became difficult, recruitment slowed, and traditional research sites faced unprecedented restrictions. Almost overnight, remote consultations, electronic consent and home-based monitoring shifted from experimental alternatives to practical necessities.
For a moment, it seemed that decentralised clinical trials (DCTs) might become the new standard. Patients would participate from home, digital technologies would replace routine site visits, and clinical research would become faster, cheaper and more accessible.
But as the pandemic faded, so did some of the initial enthusiasm. What emerged was not the fully virtual future many had imagined, but a more pragmatic approach to clinical research.
What actually survived?
Some of the most useful innovations have found a lasting place in clinical trial operations. Remote follow-up appointments, electronic consent, digital questionnaires and selected forms of home-based monitoring can reduce unnecessary travel and make participation more convenient. [3]
These changes matter particularly for patients living far from research centres, those managing chronic conditions, or those balancing treatment with work and family responsibilities.
Regulators have also adapted. In September 2024, the US Food and Drug Administration published its final guidance on clinical trials with decentralised elements, recognising approaches such as telehealth visits, home visits and the involvement of local healthcare providers. [2]
Rather than treating decentralisation as an exception, regulatory frameworks are increasingly addressing how it can be incorporated responsibly into clinical research.
Where did the promise fall short?
The idea of fully virtual clinical trials proved more complicated than it initially appeared.
Not every clinical assessment can be conducted remotely. Some studies require specialised imaging, complex procedures, direct medical supervision or tightly controlled investigational treatments. Even when digital tools are available, integrating them into established clinical workflows introduces additional responsibilities for research teams.
Technology also creates its own barriers. Participants may struggle with unfamiliar devices, unreliable connectivity or multiple digital platforms. Remote recruitment can expand geographical reach without necessarily improving representation across age groups, socioeconomic backgrounds or levels of digital literacy. [1, 3]
A 2026 analysis by researchers at ETH Zurich examined 1,370 trials with decentralised elements and found that much of the field remains focused on evaluating the feasibility and effectiveness of decentralised approaches themselves. The findings suggest that while adoption has progressed, important questions around digital equity, methodological validation and implementation remain unresolved. [1]
The rise of the hybrid trial
Perhaps the most important development is the growing emphasis on hybrid clinical trials.
Instead of replacing research sites entirely, hybrid models combine in-person assessments with remote activities wherever clinically appropriate. A participant might attend a hospital for initial screening or treatment, complete follow-up questionnaires digitally, and have selected consultations from home.
This approach recognises that decentralisation is not necessarily about removing the clinical site. It is about reducing unnecessary burdens while maintaining patient safety, data quality and scientific reliability. [2, 3]
The industry’s challenge is therefore shifting from how much of a trial can be decentralised to which activities genuinely benefit from being conducted differently.
Beyond the hype
Decentralised trials have not delivered a universal transformation of clinical research, but neither have they disappeared.
The post-pandemic period has brought a more measured understanding of where remote technologies create value and where traditional clinical infrastructure remains essential. Regulatory developments, including the modernised ICH Good Clinical Practice framework, reflect this move towards more flexible, risk-based trial design. [4]
The next phase of clinical research may be less about fully virtual trials and more about giving patients meaningful flexibility without compromising the quality of evidence.
At health.tech global summit 2027, conversations around the future of clinical research will explore how digital innovation can translate into practical, patient-centred improvements across healthcare.
The question is no longer whether clinical trials can happen outside the hospital. It is when they should.
References
1. Kijewski S, McBride C, Owens E, Bernheim E, Vayena E. Decentralized clinical trials: A comprehensive analysis of trends, technologies, and global challenges. PLOS Digital Health, 2026;5(1):e0001191. https://doi.org/10.1371/journal.pdig.0001191
2. US Food and Drug Administration. Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties. FDA, September 2024.
https://www.fda.gov/regulatory-information/search-fda-guidance documents/conducting-clinical-trials-decentralized-elements
3. Cussen A, Littler K, et al. Trial characteristics, methods and reported challenges of decentralised clinical trials: a scoping review. BMJ Open, 2025.
https://doi.org/10.1136/bmjopen-2025-106823



